2m 2m 2m 2m 2m 2m 2m
PROTARA THERAPEU (TARA)
NASDAQ
$4.30-$0.04 (-0.92%)
Price as of Jun 03, 2026 5:37 PM EDT- $261.3MMarket Cap
- 32.32%1-Year Change
- BiotechnologyIndustry
PROTARA THERAPEU (TARA)
$4.30-$0.04 (-0.92%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 9,000 N/A | N/A N/A | 0 -100.00% | 17,000 N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 9,000 N/A | 0 N/A | 0 -100.00% | 17,000 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -42.6M +34.47% | -31.7M +26.87% | -25.0M +48.67% | -16.8M -20.30% | |
Depreciation and Amortization Expense | 362,000 +9.04% | 332,000 -2.64% | 341,000 +37.50% | 248,000 +111.97% | |
Total Operating Expenses | 64.5M +31.32% | 49.2M +12.70% | 43.6M -34.97% | 67.1M +41.22% | |
Operating Profit | -64.5M +31.32% | -49.2M +12.70% | -43.6M -34.97% | -67.1M +41.22% | |
Interest Income | 6.4M +52.96% | 4.2M +30.63% | 3.2M +187.66% | 1.1M +368.35% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 6.4M +52.96% | 4.2M +30.63% | 3.2M +187.66% | 1.1M +368.35% | |
Total Nonoperating Income and Expense | 7.1M +55.99% | 4.6M +42.75% | 3.2M +187.66% | 1.1M +368.35% | |
Income before Taxes | -64.5M +31.32% | -49.2M +12.70% | -43.6M -34.97% | -67.1M +41.22% | |
Income Taxes | -11.0M -44.17% | -19.8M +43.81% | -13.8M +52.42% | -9.0M +95.11% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -57.4M +28.80% | -44.6M +10.33% | -40.4M -38.71% | -66.0M +39.58% | |
Net Income from Continuing Operations Applicable to Common | -57.4M +28.80% | -44.6M +10.33% | -40.4M -38.71% | -66.0M +39.58% | |
Basic EPS and Net Income | -1.34 -38.25% | -2.17 -39.22% | -3.57 -39.08% | -5.86 +39.19% | |
Diluted EPS and Net Income | -1.34 -38.25% | -2.17 -39.22% | -3.57 -39.08% | -5.86 +39.19% | |
Basic Weighted Average Shares | 42.8M +108.01% | 20.6M +81.73% | 11.3M +0.64% | 11.3M +0.24% | |
Diluted Weighted Average Shares | 42.8M +108.01% | 20.6M +81.73% | 11.3M +0.64% | 11.3M +0.24% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 49.7M -69.50% | 162.8M +311.25% | 39.6M +64.07% | 24.1M -32.46% | |
Short-Term Investments | 105.9M +1,313.09% | 7.5M -71.17% | 26.0M -56.85% | 60.2M +8.54% | |
Cash and Cash Equivalents and Short-Term Investments | 155.6M -8.65% | 170.3M +159.67% | 65.6M -22.27% | 84.4M -7.52% | |
Total Current Assets | 159.5M -7.35% | 172.2M +150.57% | 68.7M -20.25% | 86.1M -7.48% | |
Accumulated Depreciation | 1.5M +32.73% | 1.1M +34.22% | 824,000 +70.60% | 483,000 +104.66% | |
Property and Plant and Equipment and Net | 759,000 -26.10% | 1.0M -20.76% | 1.3M -18.59% | 1.6M -7.39% | |
Total Long-Term Assets | 3.0M -9.84% | 3.3M +11.14% | 2.9M +357.14% | 644,000 -25.55% | |
Total Assets | 209.5M +15.44% | 181.5M +129.82% | 79.0M -30.31% | 113.3M -34.36% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 10.9M -0.20% | 11.0M +78.26% | 6.1M +7.13% | 5.7M +33.55% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 2.1M -36.98% | 3.4M -25.09% | 4.5M -17.98% | 5.5M -14.36% | |
Total Liabilities | 13.1M -8.83% | 14.3M +34.68% | 10.6M -5.12% | 11.2M +4.91% | |
Retained Earnings | -302.4M +23.45% | -245.0M +22.26% | -200.4M +25.27% | -160.0M +70.15% | |
Total Stockholders Equity | 196.4M +17.52% | 167.1M +144.63% | 68.3M -33.07% | 102.1M -36.95% | |
Total Shares Outstanding | 53.6M +52.91% | 35.0M +208.36% | 11.4M +0.87% | 11.3M +0.28% | |
Cash Flow | |||||
Cash from Operating Activities | -56.4M +57.41% | -35.8M -4.66% | -37.6M +41.95% | -26.5M -23.32% | |
Capital Expenditures | 94,000 +49.21% | 63,000 +40.00% | 45,000 -62.50% | 120,000 -79.87% | |
Cash from Investing Activities | -139.5M -828.22% | 19.2M -63.93% | 53.1M +255.23% | 14.9M +115.22% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 82.7M -40.86% | 139.9M +153,797.80% | -91,000 +1.11% | -90,000 -60.53% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -717,211.11% N/A | N/A N/A | N/A N/A | -394,482.35% N/A | |
Return on Assets | -29.39% -14.20% | -34.25% -18.55% | -42.05% -8.86% | -46.14% +83.45% | |
Return on Equity | -31.60% -16.58% | -37.88% -20.15% | -47.44% -5.05% | -49.96% +90.94% | |
Revenue Growth | N/A N/A | N/A N/A | -100.00% N/A | N/A N/A | |
Current Ratio | 14.58 -7.16% | 15.71 +40.57% | 11.17 -25.55% | 15.01 -30.72% | |
Cash Ratio | 4.54 -69.44% | 14.85 +130.71% | 6.44 +53.16% | 4.20 -49.43% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow